# Treatment of Malignant Ascites Caused by Advanced Epithelial Solid Tumors With M701 Bispecific Antibody

Source: https://onco.cc/trials/nct06432296/  
OnCo record `nct06432296` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of M701 run by Wuhan YZY Biopharma Co., Ltd., active.

## Summary

Treatment of Malignant Ascites Caused by Advanced Epithelial Solid Tumors With M701 Bispecific Antibody is a phase 3 interventional study registered as NCT06432296 by Wuhan YZY Biopharma Co., Ltd., with 312 participants enrolled, started 2024-03-25. Conditions listed: Malignant Ascites. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06432296
- Phase: 3
- Setting: A Randomized, Controlled, Multi-Center Phase III Clinical Study to Evaluate the Efficacy and Safety of M701 for Intraperitoneal Injection in Patients With Malignant Ascites Caused by Advanced Epithelial Solid Tumors
- Sponsor: Wuhan YZY Biopharma Co., Ltd.
- Enrolled: 312

## Sources

- ClinicalTrials.gov NCT06432296: https://clinicaltrials.gov/study/NCT06432296

## Connected records

- drugs: [M701](https://onco.cc/drugs/m701/)
- companies: [Wuhan YZY Biopharma](https://onco.cc/companies/wuhan-yzy-biopharma/)

---
JSON: https://onco.cc/api/v1/entities/nct06432296.json